Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16887558 | 0.89 | CYP2C19 (0.75) | CYP2C19APLNR | |
| SCHEMBL31010343 | 0.88 | — | — | |
| SCHEMBL25475869 | 0.87 | CYP2C19 (0.44) | CYP2C19APLNR | |
| SCHEMBL17307627 | 0.84 | CYP2C19 (0.40) | CYP2C19APLNR | |
| SCHEMBL18212355 | 0.83 | CYP2C19 (0.41) | CYP2C19 | |
| SCHEMBL18212646 | 0.83 | CYP2C19 (0.41) | CYP2C19 | |
| SCHEMBL17298614 | 0.82 | CYP2C19 (0.39) | CYP2C19APLNR | |
| SCHEMBL23845339 | 0.82 | CYP2C19 (0.39) | CYP2C19APLNR | |
| SCHEMBL17888211 | 0.80 | CYP2C19 (0.37) | CYP2C19APLNR | |
| SCHEMBL15116507 | 0.80 | CYP2C19 (0.37) | CYP2C19APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017205309-A1 | INSULIN RECEPTOR PARTIAL AGONISTS | MERCK SHARP & DOHME CORP. (US) | 2017-11-30 | — | — | WO | disclosed |
| US-9783573-B2 | IAP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-10-10 | — | — | US | disclosed |
| US-9453048-B2 | IAP antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2016-09-27 | — | — | US | disclosed |
| US-20150322111-A1 | IAP ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2015-11-12 | — | — | US | disclosed |
| US-20150225452-A1 | IAP ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322111-A1 | IAP ANTAGONISTS | XIAP, BIRC5, API5 | CYP2C19 4883/4885APLNR 308/4885 |
| US-20150225452-A1 | IAP ANTAGONISTS | XIAP, API5, BIRC5 | CYP2C19 4883/4885APLNR 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.